ARHGAP26-IT1

Across TCGA pan-cancer cohorts, ARHGAP26-IT1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARHGAP26-IT1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARHGAP26-IT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGAP26-IT1 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

KIRC, STAD, and BRCA are the cancer types where ARHGAP26-IT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGAP26-IT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.117	<.001	8	view →
STAD	All	All	+0.190	.008	3	view →
BRCA	All	III,IV	−0.156	.009	2	view →
LUAD	All	All	+0.302	.046	1	view →
LUSC	Male	II,III,IV	−0.126	.016	1	view →
KICH	Female	All	−0.081	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARHGAP26-IT1–KIRC

Open the KIRC breakdown →